GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)), Iteos Therapeutics, Inc. ((ITOS)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GlaxoSmithKline (GSK) and iTeos Therapeutics have embarked on a Phase 3 clinical trial titled ‘GALAXIES Lung-301’ to assess the safety and efficacy of belrestotug combined with dostarlimab against pembrolizumab plus placebo in patients with PD-L1 high non-small-cell lung cancer (NSCLC). The study aims to determine improvements in progression-free survival and overall survival among participants.
The trial involves two interventions: the experimental combination of dostarlimab and belrestotug, and the active comparator of pembrolizumab with a placebo. Both interventions are biological treatments designed to target cancer cells more effectively.
This randomized, multicenter study employs a parallel intervention model with quadruple masking to ensure unbiased results. The primary purpose is treatment-focused, aiming to provide a new therapeutic option for NSCLC patients.
The study began on June 10, 2024, with an active, not recruiting status as of the last update on July 14, 2025. These dates are crucial as they mark the progression and current standing of the trial, indicating its ongoing nature.
The outcome of this study could significantly influence GSK and iTeos Therapeutics’ market positions, potentially boosting investor confidence and stock performance if successful. This trial is part of a competitive landscape in oncology, where advancements can shift market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.